Compare MOV & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOV | SANA |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.9M | 793.1M |
| IPO Year | 1996 | 2021 |
| Metric | MOV | SANA |
|---|---|---|
| Price | $33.88 | $3.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $31.50 | $7.80 |
| AVG Volume (30 Days) | 166.9K | ★ 2.4M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 44.44 | 17.24 |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $338,600,000.00 | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $0.67 | N/A |
| P/E Ratio | $40.12 | ★ N/A |
| Revenue Growth | ★ 25.73 | N/A |
| 52 Week Low | $17.27 | $2.61 |
| 52 Week High | $40.50 | $6.55 |
| Indicator | MOV | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 53.78 |
| Support Level | $22.52 | $3.82 |
| Resistance Level | $39.72 | $4.17 |
| Average True Range (ATR) | 1.10 | 0.23 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 28.08 | 51.90 |
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.